The Efficacy, Safety and Tolerability of Retapamulin as a Treatment Option for Impetigo and Other Uncomplicated Superficial Skin Infections: A Meta-analysis

Rudy Ciulianto


BACKGROUND: The treatment of impetigo, secondarily infected dermatitis and infected traumatic lesions continue to develop as new generations of drugs are being formulated. Bacteria causing impetigo show growing resistance rates for commonly used antibiotics. Retapamulin being a new drug has been recently approved as topical antibiotic in children and adult. This study aimed to ascertain the efficacy, safety and tolerability of retapamulin as the treatment option for impetigo and other uncomplicated superficial skin infections.

METHODS: A search for studies published from 2006-2014 was done in Pubmed, EBSCO, OVID, Science Direct, and Cochrane using the search strategy. The search was limited to studies conducted in human subjects and published in the English language. Randomized controlled trials evaluating the efficacy, safety and tolerability of retapamulin as treatment for impetigo and other uncomplicated superficial skin infections in children and adult were included and extracted independently and the qualities of the studies were appraised using critical appraisal tools. Data analysis was conducted by using RevMan 5.

RESULTS: This study has high heterogeneity and found Retapamulin has no statistically significant difference in the clinical success after seven days and follow up among per-protocol-patients, bacteriogical confirmed patients and intention-to-treat patients with impetigo and other secondary infected traumatic lesions compared to other regimens. However, Retapamulin has beneficial effect in the clinical success, well tolerated and safe for children and adults.

CONCLUSION: Retapamulin is comparably effective and safe as a treatment option for impetigo and other uncomplicated superficial skin infections.

KEYWORDS: efficacy, safety, tolerability, retapamulin, impetigo, meta-analysis

Full Text:



Perera G, Hay R. A guide to antibiotic resistance in bacterial skin infections. J Eur Acad Dermatol Venereol. 2005; 19: 531-45, CrossRef.

Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician. 2007; 75: 859-64, PMID.

Hedrick J. Acute bacterial skin infections in pediatric medicine: Current issues in presentation and treatment. Pediatr Drugs. 2003; 5 (Suppl 1): 35-46, PMID.

Stulberg DL, Penrod MA, Blatny RA. Common bacterial skin infections. Am Fam Physician. 2002; 66: 119-24, PMID.

Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005; 41: 1373-406, CrossRef.

Koning S, Verhagen AP, van Suijlekom-Smit LW, Morris A, Butler CC, van der Wouden JC. Interventions for impetigo. Cochrane Database Syst Rev. 2004; (2): CD003261, PMID.

Laube S, Farrell AM. Bacterial skin infections in the elderly: diagnosis and treatment. Drugs Aging. 2002; 19: 331-42, CrossRef.

Roberts S, Chambers S. Diagnosis and management of Staphylococcus aureus infections of the skin and soft tissue. Intern Med J. 2005; 35 (Suppl 2): S97-105, CrossRef.

Ladhani S, Garbash M. Staphylococcal skin infections in children: rational drug therapy recommendations. Pediatr Drugs. 2005; 7: 77-102, CrossRef.

Electronic Medicines Compendium [homepage on the Internet]. Fucidin (fusidic acid) cream: UK prescribing information [Accessed 2007 Oct 9]. Available from:

Electronic Medicines Compendium [homepage on the Internet]. Bactroban® (mupirocin) 2% ointment: UK prescribing information [Accessed 2007 Oct 9]. Available from:

GlaxoSmithKline [homepage on the Internet]. Bactroban Ointment® (mupirocin 2% ointment): US prescribing information [Accessed 2007 Oct 9]. Available from:

Afset JE, Maeland JA. Susceptibility of skin and soft-tissue isolates of Staphylococcus aureus and Streptococcus pyogenes to topical antibiotics: indications of clonal spread of fusidic acid-resistant Staphylococcus aureus. Scand J Infect Dis. 2003; 35: 84-9, CrossRef.

Shah M, Mohanraj M. High levels of fusidic acid-resistant Staphylococcus aureus in dermatology patients. Br J Dermatol. 2003; 148: 1018-20, CrossRef.

Dobie D, Gray J. Fusidic acid resistance in Staphylococcus aureus. Arch Dis Child. 2004; 89: 74-7, CrossRef.

Cookson BD. Mupirocin resistance in staphylococci. J Antimicrob Chemother. 1990; 25: 497-501, CrossRef.

Cookson BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother. 1998; 41: 11-8, CrossRef.

Deshpande LM, Fix AM, Pfaller MA, Jones RN. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis. 2002; 42: 283-90, CrossRef.

European Medicines Agency [homepage on the Internet]. Summary of product characteristics: product information (Altargo) [Accessed 2008 Mar 26]. Available from:

GlaxoSmithKline [homepage on the Internet]. Altabax™ (retapamulin 1% ointment): US prescribing information [Accessed 2007 Aug 24]. Available from:

European Medicines Agency [homepage on the Internet]. Tiamulin: summary report from the Committee for Veterinary Medicinal Products [Accessed 2007 Oct 31]. Available from:

Pretorius J. Skin and soft-tissue infections: the early clinical presentation of soft-tissue infections may be deceptive. CME. 2010; 28: 265-9, article.


Copyright (c) 2015 The Prodia Education and Research Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Indexed by:






The Prodia Education and Research Institute